Get started

Biotech

Hold your breath peopleIf you have viewed my posts about IBIO , you would have witness the long term yellow line cutting through the 1.6-1.8 price point. Either this drop is to retest the long term channel or ... well... good luck to those that still believe in the company. I like the innovative company and the CEO's track record and was invested since $0.3. I really appreciate the person that referred me to IBIO on yahoo chatroom in Feb. I have started to trimmed my position when this started to breaking through all the support level like a hot knife through butter below the $3 dollar range. Wish the bulls good luck! just need one proper PR and this beast will rocket. stay safe! Side thought: I have seen in many chatroom and witness many high PT for all different kind of ticker (i guess you reading this have as well). Especially, 'this company has XXX product and it deserve XXX price' ,' this company will save the world '. I mean i am sure that biotech companies have all the smartest people in the world and they deserve tremendous net worth for all they have done for humanity, but unfortunately, this is a money society.Invest safe and wise people. Companies pulling moves like Novavax and Overstock are rare; i believe it is more luck than any other reason.
AMEX:IBIO
by jordanadriano
4
breaking out in a few days? PT 17-18In my previous idea, i stated that IBIO would consolidate around mid 4 area until next breakout but it was not how it ended. With Russian news and insider dumping, IBIO went back all the way to its breakout point. Currently, it is touching the trend drawn all the way from the beginning of the year that connects two breakout point (green line, breakout points are drawn in blue). Is it ready for a run? If it runs, i expect PT of 17-18 then retracement. retracement levels shown on figure (10 dollar, worst case scenario $6-7)
AMEX:IBIOLong
by jordanadriano
6
NSPR still dippingOkay I'm gonna start off with the news News -NSPR beat earnings by 44%, yet still losing money. It has been making more money due to its past performance and not losing as much. We can project that they might be profitable next year. -Their offering that was held in June came out that it was so they can remain compliant with the exchange. That Friday they have became fully compliant so they won't get delisted. -On their earnings report they got mostly compliant FDA IDE approval, yet on that they will get fully compliant FDA IDE approval in 45days. This should be on the 27th, so next week, which I labeled on the graph. -Upcoming catalist: they hope to get into the France and China markets soon. Plus with approval in Brazil we could see that profit from the company in q4/ another earnings beat. Maybe over 100%, yet with COVID not sure, but certain in q1 next year. TA -Not sure what to say since an earnings beat should have pushed the price higher, yet we saw a sell off with no FDA IDE approval to common investors liking. At the same time the volume showed it being very low compared to the past showing its just small sellers and yesterday someone bought 200k shares touching our old trading zone. -the low at .4194 was in the middle of the gap of the intial drop from .80 to .39 then gaping up to .42-.47 Final thoughts I'm DCAing this stock and think its gonna pay off pretty soon. Recent SEC filing shows that their CFO has sign a contract starting in 2022 that he will get an annual renewal of his job. This shows there is some long term potential if a CFO is entering this contract and wants to see growth in this company or he will get fired. There was alot more in the earnings report like and they don't want to do any more offerings and they also have alot of cash on hand to play with, so upside potential is pretty high.
NLong
by nathanielx9
ArcticZymes turnaround & firing on all cylindersThe Turnaround of ArcticZymes is now definitive. For the second quarter we see impressive growth and the company is firing on all cylinders. Opex (cost) going down while earnings as well as profits surge. ArcticZymes Q2 report Sales of NOK 44.3 million (16.9) +262% EBITDA of NOK 27.2 million (-0.5) Cash-flow for the Q2 was NOK 20.4 million (-6.8) Cash at hand NOK 56,1 million Gross margin 90% CEO Jethro Holter says in the earnings call: "The main growth driver has been sales of the Salt Active Nuclease (SAN) products to the therapeutics segment. The SAN products continue to attract new customers who are developing gene therapies and vaccines. Furthermore, our well-established customers are regularly submitting substantially larger orders as they advance their development programs." Full report pdf here: newsweb.oslobors.no text: newsweb.oslobors.no
OSL:AZTLong
by kulturdesken
2
GNBT: Penny stock, speculative biotech to considerUp sharply today on news (see below) Looks to me like forming a likely inverse head and shoulders pattern. Often with H&S there is a fairly symmetrical time difference between and shoulders and the top or bottom as we have here (horizontal arrows). Like all biotechnology stocks this could be a bust or very volatile. "Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia."
GLong
by goodguy
2
Merck a strong value with strong technicals and upcoming newsI've been holding Merck since its big dip to $76 back in June. At the time I set a price target of $82: However, I didn't sell at $82 and have continued to hold the stock due to strong fundamentals, technicals, news, and sentiment. Merck has positive earnings and sales growth, with PEG ratio of 1.7 and PSG ratio of 2.3. It has a nice dividend yield at 2.9%, a rarity for a stock with such strong growth. Analysts rate it highly, with an average score of 80.25/100 from S&P Global and an Equity Starmine Summary Score of 8.5/10. With a put/call ratio of 0.41, sentiment on Merck is stronger than on most of the other stocks I watch. It's got a good ESG score and a long history of beating analyst estimates. Plus it's poised to benefit from some hype around its antiviral drug intended to fight Covid-19 that starts clinical trials in September. In technical terms, Merck recently broke out of a triangle, got a couple bullish moving average crosses, and today broke out above its recent trading range. If Merck oscillates down to its moving averages, I may use that as an opportunity to add to my position. I think the stock still has plenty of upside, especially when the clinical trial headlines start to hit.
NYSE:MRKLong
by ChristopherCarrollSmith
[NVAX] Novavax: Preliminary studies produce promising resultsPreliminary studies on coronavirus vaccines have produced promising results. I'm still a believer in their technology. Check out my previous NVAX posts and/or the first one. They have a promising technology that could revolutionize the vaccine industry. We (humanity) are already very behind in how we produce vaccines AKA using chicken eggs. So Novavax will hopefully pave the way for vaccines going forward. Things to watch even after COVID-19: - NanoFlu™ - ResVax™ - Recombinant Nanoparticle Vaccine Technology - Matrix-M™ Adjuvant Technolog TL;DR - To the moon and (probably) back lol *Note: This is pure speculation and my own opinion* NY Times: www.nytimes.com CNBC: www.cnbc.com
NASDAQ:NVAXLong
by traderman001
2
GENE: Last Breakout was Crazy, High Volume Pop?GENE is one of those stocks that had support pickup for volume which lead to a really big breakout. The selloff was as bad, given many people getting excited can leave just as quick. I'm not sure I would consider it far enough evidence yet for market manipulation. That being said, even with lots of the resistance it has been receiving, I think it has potential for a positive retest. I would rate this as mid risk, but think that bullish correlations can push this past the $7 price point quite soon. That being said, please do your own due diligence. Invest at your own risk. Everything I say is on an opinion based basis.
GLong
by gamer456148
1
What to expect on ER?Well seems like we continue the sell off of the Brazil news that I didn't sell. So what news is there to push it higher? Well if ER repeats the same pattern we can suspect them beating EPS and and Beating Revenue. News -Earnings this wednesday, a week early -They are hitting their road map this year www.inspiremd.com -Atm the FDA IDE is awaiting its pr, yet questions on their recent tweet suggesting it got approved twitter.com -The filed for some 8-ks on a past offering that happen over two years ago. These changed the pricing of these investors to .49-.50. Heres some links to the offering it refers too and to a definetion to prospectus supplement. www.globenewswire.com prospectus supplement definition: the link looks funny so just google the definition Now TA -We been in a downward trend, yet the volume has been low. The average volume ranges from 2.5-over 4million, yet the past week its been dropping and Friday we didn't even hit a million. The only thing I could find is a low volume downward trend article titled "Low Volume Pullback" Again we going back to the FDA IDE news that many common investors suspect the news to already be dropped. Now I'm no expert on how this process works, so I'm just waiting till ER update. www.investopedia.com -MACD looks like its gonna turn over, but is neutral on that it is possible for a pretty big move this week in either direction. -RSI is trending downward suggesting its becoming oversold and we could go bullish, yes it's not super oversold yet. -I put in a new trade zone that we could just go sideways till earnings from .4499-.4594 Other notes -I did some DD on the current CEO and notice over 2 years he produces returns for a company from when he gets hired till he leaves. If you can hold for another year and 2/3months you could see a price target of .9023 or a pt of 1.2293. This data is from his recent jobs at ticker ITAMAR and IART, which he produced returns at rougly round 4-44% as he worked for them. -According to Fintel: on 06/09/2020 Lind Global Macro Fund LP acquired just over 3.9million shares and L1 Capital Global Opportunities Master Fund, Ltd acquired over 650k shares on 06/19/2020 fintel.io Final thoughts I'll hold my position, but till earnings. I'll be neutral on the buy half, yet long term you could make 100%-170% return in the next year and 3 months with the CEO past performance. They have hit the Brazil market and is growing in the US. You could see massive market cap growth.
N
by nathanielx9
Easy money here. Long $QLGNKeeping the great winning streak ratio alive. CEO is great here - knows about value. I quote from his shareholders letter: "...we believe our plans will help build significant shareholder value..." This means HI GUYS, BUY MY STOCK (lol) These guys have the FASTEST COVID antibody test kit on the market (10 minutes vs Becton Dickinson's 15 minute kit) - it is currently SELLING and shortly we will see the FDA EUA PR. In addition to all of this, company just closed a great offering for 8M at 5.25 - so the chart and that round is essentially backing you here. Kicker warrants are priced WAY out of the money so no dilution there. All the main weekly oscillators SCREAM buy now - so this one is easy. Ride the wave and if there are some hiccups you add on dips, this chart is also NOTORIOUS for epic multibagger runs. Long for the swing! Strong buy NOW
NASDAQ:QLGNLong
by GK-Trades
1
Why I am Long on $MMEDFRight now one of the stocks that have my attention, (partly because of Kevin O'Leary) and the rest of its history is Mind Medicine (MindMed Inc.) They are one of the first companies finding a way to neutralize LSD while working on a DMT based therapy drug. Also, the market cap and entry is low. This is one of those stocks where you need to dig deep into the pitch deck and look at competition, market opportunities, and entry price. Right now as a biotech company, it is one of my favorite low priced biotech stocks, and as a long hold in somebody's portfolio, I don't think the risk aversion is too high. That being said, everything I say is on an opinion based basis. Please proceed with caution and invest at your own risk. Do your own due diligence.
MLong
by gamer456148
1
$ACOR can rise in the next daysContextual immersion trading strategy idea. Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $0,86; stop-loss — $0,81. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
ALong
by KozakHlib
Biogen trend line to watchBiogen today reported a huge earning beat, but disappointing guidance for the rest of the year. When you crunch the numbers, the midpoint of Biogen's guidance range for 2H 2020 came in slightly below Street consensus for both earnings and revenues. Biogen has a reasonable, but not great valuation, with forward PEG of 3.78 and forward PSG of 1.27. It's currently in the lower half (26th percentile) of its three-year valuation range in terms of forward P/S and forward P/E. Biogen pays no dividend, and as a result the stock is more volatile than a dividend-paying stock would be. Sentiment on Biogen improved quite a bit today. There have been no analyst upgrades yet, but options traders moved from net-bearish to net-bullish positioning for the short term, and from net-bearish to net-neutral positioning for the long term. We're coming up on the strong season for pharmaceutical stocks in August. Biogen has only one phase 2 clinical trial result due in the second half of 2020 for its multiple sclerosis drug, but there are five results due in the first half of 2021, including a phase 3. These could prove to be major catalysts for the stock over the next year. For the near term, watch for a possible trend line break as a sign that the stock will move higher.
NASDAQ:BIIB
by ChristopherCarrollSmith